Jefferies has reiterated its Buy rating on Entero Health, increasing the target price to ₹1,680 from ₹1,510, suggesting a potential upside of 20.9% from the current market price (CMP) of ₹1,390. The brokerage noted that Q2 results were in line with expectations, and Entero Health has maintained its FY25 revenue growth guidance of 35-40%. The company completed nine acquisitions in FY25, achieving FY24 revenue of ₹750 crore.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult a financial advisor before making any investment decisions.
